Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. SOC in Patients With Recurrent Glioblastoma.
In: AIDS Weekly, 2024-04-08, S. 108-108
serialPeriodical
Zugriff:
This article provides information about a clinical trial, NCT06325683, that is investigating the safety and effectiveness of two different treatments for recurrent glioblastoma, a type of brain cancer. The trial will compare the use of anti-lag-3 (relatlimab) and anti-PD-1 blockade (nivolumab) to the standard chemotherapy drug lomustine. The study will measure overall survival, progression-free survival, radiographic response, and adverse events as primary and secondary outcomes. The trial is set to begin in June 2024 and aims to enroll 178 participants. The document also includes information about the procedures involved in the trial, such as biopsies, biospecimen collection, and magnetic resonance imaging. [Extracted from the article]
Copyright of AIDS Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. SOC in Patients With Recurrent Glioblastoma.
|
---|---|
Zeitschrift: | AIDS Weekly, 2024-04-08, S. 108-108 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1532-4524 (print) |
Schlagwort: |
|
Sonstiges: |
|